Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... Feature Extraction Software reads and ... to prepare microarray data for ... one 1-year license for ... accounts , * one ...
... AquaMax DW4 liquid handling system from Molecular ... all in one instrument. The system handles ... and plate washing96-, 384- and 1536-welland is ... AquaMax DW4 has been optimized to dispense ...
... 10 O 2 S 2 ... White crystalline powder Assay: greater than ... IR Melting Point: greater than or ... than or equal to 1% ...
Biology Products:(Date:12/4/2009)... Centre for Advanced Micro Nano Technology Products (ACAMP) ... , EDMONTON, Dec. 4 /PRNewswire/ - Today ACAMP ... technologies like nanotechnology, biomaterials and microfluidics can play ... healthcare products that help promote health and improve ...
(Date:12/3/2009)... of Houston, LLC announced today that it has ... option, vertical sleeve gastrectomy , along with the ... first sleeve gastrectomy procedure at the facility was performed ... on October 20, 2009. The patient is reported as ...
(Date:12/3/2009)... FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: ... of compounds for the treatment of cardiovascular and metabolic ... patient visit in its Phase 2 FDG-PET clinical trial ... patients and was carried out at five sites in ...
(Date:12/3/2009)... WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: ... to take charge of their health at home through the ... dividend of $3.00 per share on its Series B Convertible ... in shares of Series B stock in an amount per ...
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4